Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026)
Vericel (VCEL) posted Total Non-Current Liabilities of $130.9 million for Q2 2026, up 2.66% sequentially from $127.5 million in Q1 2026, and up 2.96% YoY from $127.1 million in Q2 2025.
Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Vericel has reported Total Non-Current Liabilities for 17 years, with the latest figure at $130.9 million in Q2 2026.
- Quarterly Total Non-Current Liabilities rose 2.96% year-over-year to $130.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $130.9 million (up 2.96% YoY) and the FY2025 annual result came in at $131.4 million, down 6.04% from the prior year.
- Total Non-Current Liabilities climbed to $130.9 million in Q2 2026 per VCEL's latest filing, from $127.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $139.9 million in Q4 2024 and troughed at $67.8 million in Q1 2022.
- A 5-year average of $114.4 million and a median of $127.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 61.98% in 2023, then slipped 6.04% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $80.7 million in 2022, then soared by 58.06% to $127.6 million in 2023, then climbed by 9.62% to $139.9 million in 2024, then declined by 6.04% to $131.4 million in 2025, then declined by 0.4% to $130.9 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $130.9 million, $127.5 million, and $131.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 130.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.91 Mn |
| Mar 31, 2026 | 127.52 Mn |
| Dec 31, 2025 | 131.43 Mn |
| Sep 30, 2025 | 129.74 Mn |
| Jun 30, 2025 | 127.14 Mn |
| Mar 31, 2025 | 127.25 Mn |
| Dec 31, 2024 | 139.88 Mn |
| Sep 30, 2024 | 132.69 Mn |
| Jun 30, 2024 | 133.66 Mn |
| Mar 31, 2024 | 122.61 Mn |
| Dec 31, 2023 | 127.61 Mn |
| Sep 30, 2023 | 113.68 Mn |
| Jun 30, 2023 | 111.76 Mn |
| Dec 31, 2022 | 80.73 Mn |
| Sep 30, 2022 | 70.18 Mn |
| Jun 30, 2022 | 69.98 Mn |
| Mar 31, 2022 | 67.78 Mn |
| Dec 31, 2021 | 73.20 Mn |
| Sep 30, 2021 | 67.32 Mn |
| Jun 30, 2021 | 70.79 Mn |